Meropenem Clinical Trials

Size	Price	Qty
25mg	USD 147

Clinical Trials

Numerous clinical trials evaluate the therapeutic utility and pharmacokinetic profiles of meropenem across diverse indications, including severe bacterial infections, hospital-acquired pneumonia, febrile neutropenia, melioidosis, septic shock, and post-cardiac surgery or ECMO complications. Spanning Phase 1 through Phase 4, early feasibility, and non-applicable phase designations, these studies are sponsored by academic medical centers and health organizations such as University Hospital Grenoble, Wake Forest University Health Sciences, and Oslo University Hospital. The trials reflect various recruitment statuses, including recruiting, completed, terminated, and withdrawn protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07759453	NOT_YET_RECRUITING	Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization	IRCCS Azienda Ospedaliero-Universitaria di Bologna	2026-10-01	PHASE3
NCT07004049	RECRUITING	Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance	National University of Singapore	2025-04-21	PHASE4
NCT06184659	RECRUITING	Sepsis; Septic Shock	Scandinavian Critical Care Trials Group	2025-06-26	PHASE4
NCT07556107	RECRUITING	Infection; Acute Kidney Injury; Sepsis	Bassett Healthcare	2026-08-17	PHASE4
NCT07327619	RECRUITING	Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia	Qilu Pharmaceutical Co., Ltd.	2026-01-22	PHASE3
NCT07484633	NOT_YET_RECRUITING	Infection; Sepsis; NICU; PICU; Beta Lactams	Semmelweis University	2026-04	PHASE4
NCT05925309	RECRUITING	Biliary Atresia; Cholangitis; Anti-Bacterial Agents	Children's Hospital of Fudan University	2023-07-01
NCT07326540	RECRUITING	Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC; Acinetobacter Baumannii-calcoaceticus Complex	BioVersys SAS	2026-03-27	PHASE3
NCT07512596	RECRUITING	Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2026-07-21	PHASE2
NCT06168734	WITHDRAWN	Ventilator-associated Pneumonia; Hospital-acquired Pneumonia	Venatorx Pharmaceuticals, Inc.	2025-06	PHASE3
NCT06633718	NOT_YET_RECRUITING	Intra-abdominal Infections	Qilu Pharmaceutical Co., Ltd.	2024-10-31	PHASE3
NCT07314281	RECRUITING	Enteric Fever	Indus Hospital and Health Network	2025-04-22	PHASE4
NCT07641348	NOT_YET_RECRUITING	Typhoid Fever	Iqra Asghar Ali	2026-07-01
NCT03671967	RECRUITING	Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia	Rambam Health Care Campus	2019-05-01	PHASE4
NCT06672978	ACTIVE_NOT_RECRUITING	Acute Pyelonephritis; Complicated Urinary Tract Infection	Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)	2025-06-03	PHASE2
NCT06818565	NOT_YET_RECRUITING	Acute-On-Chronic Liver Failure	Institute of Liver and Biliary Sciences, India	2025-02-10
NCT06342115	RECRUITING	Febrile Neutropenia	Beneficência Portuguesa de São Paulo	2025-03-26	PHASE4
NCT07089186	RECRUITING	Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI); Bloodstream Infection (BSI)	Qilu Pharmaceutical Co., Ltd.	2025-04-12	PHASE3
NCT05578586	RECRUITING	Drug Effect	Oslo University Hospital	2021-12-14
NCT07694700	ACTIVE_NOT_RECRUITING	MDR Bacteria	Beni-Suef University	2025-12-30	PHASE4
NCT07524920	NOT_YET_RECRUITING	MDR Bacteria	Ain Shams University	2026-04-01	PHASE2
NCT06426836	RECRUITING	Pharmacokinetics; Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem; Cefazolin; Teicoplanin; Vancomycin; Ciprofloxacin; Amikacin	University Hospital, Ghent	2016-08-19
NCT02687906	COMPLETED	Bacterial Infections	Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)	2016-07	PHASE1
NCT06828848	RECRUITING	Gram Negative Infections	Menarini Group	2025-02-18	PHASE2
NCT05922124	RECRUITING	Carbapenem Resistant Bacterial Infection; Acinetobacter Bacteremia; Acinetobacter Pneumonia	Rambam Health Care Campus	2024-09-01	PHASE4
NCT05565222	UNKNOWN	Sepsis; Septic Shock	Assistance Publique - Hôpitaux de Paris	2023-03-11	PHASE3
NCT06198764	UNKNOWN	Mental Health Issue	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2023-07-06	PHASE3
NCT06293677	UNKNOWN	Febrile Neutropenia	Centre Hospitalier Universitaire Vaudois	2024-03-01	PHASE4
NCT06841731	RECRUITING	Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)	Jiangsu HengRui Medicine Co., Ltd.	2025-04-03	PHASE2
NCT07096310	ACTIVE_NOT_RECRUITING	Sepsis	Ain Shams University	2024-01-01	PHASE1; PHASE2
NCT03630081	UNKNOWN	Complicated Urinary Tract Infection; Acute Pyelonephritis	Wockhardt	2024-01	PHASE3
NCT07124468	RECRUITING	Infections	Qilu Pharmaceutical Co., Ltd.	2025-09-13	PHASE1
NCT07445282	COMPLETED	Extensively Drug-Resistant Typhoid Fever; Typhoid Fever; Salmonella Typhi Infection	Sheikh Zayed Medical College	2025-05-14	PHASE4
NCT06916156	COMPLETED	Pharmacokinetics Study on Healthy Volunteers Adults	Antabio	2025-04-28	PHASE1
NCT05355350	WITHDRAWN	Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia	Rambam Health Care Campus	2022-07-01	PHASE4
NCT06527677	COMPLETED	Renal Impairment	Antabio	2024-07-19	PHASE1
NCT05204368	UNKNOWN	Complicated Urinary Tract Infection Including Acute Pyelonephritis	Evopoint Biosciences Inc.	2023-03-30	PHASE3
NCT06026852	UNKNOWN	Infections	University Hospital, Ghent	2024-09-26
NCT05784844	WITHDRAWN	Febrile Neutropenia	Wake Forest University Health Sciences	2024-08	PHASE4
NCT05393505	UNKNOWN	Neutropenic Fever	The University of Hong Kong	2022-10-24	PHASE4
NCT04809259	UNKNOWN	Infection, Bacterial	University of Lausanne Hospitals	2024-01-01	EARLY_PHASE1
NCT04478721	COMPLETED	Bacteremia	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2020-12-15	PHASE3
NCT03891433	SUSPENDED	Urinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem; Escherichia Coli Infection; Klebsiella Pneumoniae Infection; Clinical Trial; Drug Resistance, Bacterial	Universidad del Norte	2019-04-01	PHASE4
NCT04979806	COMPLETED	Complicated Urinary Tract Infection; Acute Pyelonephritis	Wockhardt	2022-08-28	PHASE3
NCT07681544	COMPLETED	Empirical Antimicrobial Therapy; Critically Ill; Meropenem; Pharmacokinetics and Pharmacodynamics	Hospital Italiano de Buenos Aires	2024-06-26
NCT06338345	Not yet recruiting	Cardiogenic Shock\|Post-cardiac Surgery\|Cardiac Arrest\|Extracorporeal Membrane Oxygenation Complication\|Infections	University Hospital Grenoble	2024-09-01	Not Applicable
NCT07122596	COMPLETED	Sepsis; Bacterial Infection	Pakistan Navy Station Shifa Hospital	2024-04-01	PHASE4
NCT04238390	WITHDRAWN	Bacteremia Caused by Gram-Negative Bacteria	The University of Queensland	2022-01	PHASE3
NCT05784844	Recruiting	Febrile Neutropenia	Wake Forest University Health Sciences	2024-04	Phase 4
NCT05905913	COMPLETED	Healthy Volunteers	Antabio	2023-04-12	PHASE1
NCT05427747	UNKNOWN	Spontaneous Bacterial Peritonitis	Assiut University	2023-01-01	PHASE4
NCT04809259	Not yet recruiting	Infection Bacterial	University of Lausanne Hospitals	2024-01-01	Early Phase 1
NCT06087536	Not yet recruiting	Hospital-acquired Bacterial Pneumonia\|Ventilator-associated Bacterial Pneumonia	Omnix Medical Ltd	2024-01	Phase 2
NCT05340530	UNKNOWN	Infections	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2022-04	PHASE1
NCT06089668	Recruiting	Melioidosis	AN2 Therapeutics Inc\|Mahidol Oxford Tropical Medicine Research Unit	2023-11-01	--
NCT05105035	COMPLETED	Melioidosis	Arrevus Inc.	2022-06-14	PHASE2
NCT04983901	COMPLETED	Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm	M.D. Anderson Cancer Center	2021-09-14	PHASE2
NCT04816968	UNKNOWN	Severe Bacterial Infections	Ospedale San Carlo Borromeo	2021-09	PHASE1
NCT05102162	TERMINATED	Pneumonia	University of Florida	2021-12-17	PHASE4
NCT03329092	COMPLETED	Complicated Intra-abdominal Infection; Hosptial Acquired Pneumonia; Ventilator Associated Pneumonia	Pfizer	2018-04-05	PHASE3
NCT05392634	UNKNOWN	Bladder Cancer	N.N. Petrov National Medical Research Center of Oncology	2022-02-02	PHASE3
NCT04785924	WITHDRAWN	Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection	Wake Forest University Health Sciences	2021-06-07	PHASE4
NCT03452839	COMPLETED	Antibiotic Resistant Infection; Critical Illness	Università Vita-Salute San Raffaele	2018-06-05	PHASE4
NCT05226923	COMPLETED	Bacterial Infections	Sumitovant Biopharma, Inc.	2022-01-12	PHASE1
NCT07113574	COMPLETED	Peritoneal Dialysis Associated Peritonitis; Peritoneal Dialysis (PD); Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Meropenem; Aztreonam; Antibacterial Agents; Intraperitoneal Antibiotics; Kidney Failure, Chronic; Anti-Bacterial Agents; Drug Therapy	Karl Landsteiner Insitute for Nephrology and Haemato-Oncology	2021-08-31	PHASE2; PHASE3
NCT04671589	UNKNOWN	Drug Toxicity	Mabaret Al-Asafara Hospitals	2021-06	PHASE4
NCT03174184	COMPLETED	Tuberculosis, Pulmonary	Johns Hopkins University	2017-08-23	PHASE2
NCT05060419	UNKNOWN	Complicated Urinary Tract Infection; Acute Pyelonephritis	Qilu Pharmaceutical Co., Ltd.	2021-10-08	PHASE2
NCT04876430	TERMINATED	Carbapenem-Resistant Enterobacteriaceae Infection; Bloodstream Infection	Hospital de Clinicas de Porto Alegre	2021-05-04	PHASE2; PHASE3
NCT04555798	COMPLETED	Patients With Respiratory Failure and Shocked	Mohamed Gaber Allam	2022-02-01	PHASE1; PHASE2
NCT04233996	UNKNOWN	Febrile Neutropenia	Hospital Universitari de Bellvitge	2019-06-05	PHASE4
NCT03840148	COMPLETED	Urinary Tract Infections; Acute Pyelonephritis	Venatorx Pharmaceuticals, Inc.	2019-08-07	PHASE3
NCT06739382	COMPLETED	Ventilation Acquired Pneumonia	Beni-Suef University	2021-01-01	PHASE3
NCT06072222	COMPLETED	ARDS; Septic Shock	King Abdul Aziz Specialist Hospital	2020-07-02	PHASE1; PHASE2
NCT04553367	COMPLETED	ARDS; Septic Shock	King Abdul Aziz Specialist Hospital	2020-07-02	PHASE1; PHASE2
NCT06072248	COMPLETED	ARDS; Septic Shock	King Abdul Aziz Specialist Hospital	2020-07-02	PHASE1; PHASE2
NCT04370145	COMPLETED	Cholangitis, Secondary Biliary; Treatment Compliance; Antibodies Drug Specific	Tongji Hospital	2021-05-01	PHASE4
NCT03717350	UNKNOWN	Sepsis	Hellenic Institute for the Study of Sepsis	2018-10-27	PHASE2; PHASE3
NCT04629378	COMPLETED	Tuberculosis	TASK Applied Science	2020-08-17	PHASE2
NCT03485950	COMPLETED	Other Infectious Diseases	M.D. Anderson Cancer Center	2018-05-16	PHASE2
NCT05058105	COMPLETED	Healthy	Qilu Pharmaceutical Co., Ltd.	2020-10-08	PHASE1
NCT05896930	COMPLETED	Pulmonary Tuberculosis	TASK Applied Science	2017-11-09	PHASE2
NCT02437045	COMPLETED	Bloodstream Infections	The University of Queensland	2015-04	PHASE4
NCT04154722	COMPLETED	Typhoid Fever	Ziauddin University	2019-06-20	PHASE4
NCT03230838	COMPLETED	Complicated Urinary Tract Infection; Pyelonephritis	Merck Sharp & Dohme LLC	2018-04-26	PHASE2
NCT03543436	COMPLETED	Urinary Tract Infections	Assistance Publique - Hôpitaux de Paris	2019-01-04	PHASE3
NCT03830333	COMPLETED	Complicated Intra-abdominal Infections	Merck Sharp & Dohme LLC	2019-03-20	PHASE3
NCT01597973	COMPLETED	Pneumonia; Blood Stream Infection	University of Michigan	2012-10-06	PHASE3
NCT04489459	UNKNOWN	Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae	Al-Azhar University	2019-09-21	PHASE4
NCT03006679	WITHDRAWN	Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia; Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia	Melinta Therapeutics, Inc.	2018-08	PHASE3
NCT03217136	COMPLETED	Complicated Intra-Abdominal Infection	Merck Sharp & Dohme LLC	2018-04-03	PHASE2
NCT02047773	COMPLETED	Bronchiectasis	University of Edinburgh	2014-01	PHASE4
NCT03019965	COMPLETED	Sepsis	Coordinación de Investigación en Salud, Mexico	2017-02-01
NCT03884881	UNKNOWN	Pneumonia; Metagenomic Next Generation Sequencing	Xiangya Hospital of Central South University	2018-01-01
NCT03645668	COMPLETED	Sepsis	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	2018-01-30	PHASE4
NCT02149329	COMPLETED	Febrile Neutropenia; Hematological Malignancy	Amsterdam UMC, location VUmc	2014-12	PHASE4
NCT03915236	TERMINATED	Lower Respiratory Tract Infection	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	2019-02-18
NCT03032380	COMPLETED	Healthcare-associated Pneumonia (HCAP); Hospital Acquired Pneumonia (HAP); Ventilator Associated Pneumonia (VAP)	Shionogi	2017-10-24	PHASE3
NCT02142751	COMPLETED	Infection Due to ESBL Escherichia Coli	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2014-07	PHASE3
NCT03344627	COMPLETED	Sepsis; Septic Shock; Critical Illness; Carbapenem; Pharmacokinetic; Pharmacodynamic; Clinical Outcome; Organ Failure, Multiple; Morality	Mahidol University	2017-11-27
NCT03564158	COMPLETED	Healthy	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	2018-05-01	PHASE1
NCT02820987	COMPLETED	Septic Shock	Centre Hospitalier Universitaire de Besancon	2016-09-27	PHASE3
NCT03157388	COMPLETED	Alcoholic Hepatitis	University of Aarhus	2017-06-01
NCT02070757	COMPLETED	Healthcare-Associated Pneumonia; Ventilator-Associated Pneumonia; Lung Diseases	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2014-09-02	PHASE3
NCT03174795	COMPLETED	Urinary Tract Infections	Hoffmann-La Roche	2017-07-11	PHASE1
NCT02840136	TERMINATED	Cystic Fibrosis	University Ghent	2016-02
NCT03182504	COMPLETED	Gram-negative Bacterial Infections	Hoffmann-La Roche	2017-06-15	PHASE1
NCT02168946	COMPLETED	Urinary Tract Infection Complicated; Acute Pyelonephritis; Hospital Acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Abdominal Infection	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	2014-07	PHASE3
NCT02788240	TERMINATED	Acute on Chronic Liver Failure	Institute of Liver and Biliary Sciences, India	2016-05-01
NCT02176122	TERMINATED	Bloodstream Infections	The University of Queensland	2014-02	PHASE4
NCT07113587	COMPLETED	Peritoneal Dialysis-associated Peritonitis; Peritoneal Dialysis (PD); Pharmacokinetics; Intravenous Administration; Intravenous; Meropenem; Intraperitoneal; Ampicillin; Aztreonam; Ciprofloxacin; Minimum Inhibitory Concentration (MIC)	Karl Landsteiner Insitute for Nephrology and Haemato-Oncology	2014-04-08	PHASE2; PHASE3
NCT01667094	UNKNOWN	Cystic Fibrosis	The Alfred	2012-09	PHASE4
NCT02475733	COMPLETED	Complicated Intra-abdominal Infections	Pfizer	2015-08-01	PHASE2
NCT01828892	UNKNOWN	Low-output External Gastrointestinal Fistula	Jinling Hospital, China	2014-03
NCT02463747	UNKNOWN	Fever; Febrile Neutropenia	Tel-Aviv Sourasky Medical Center	2015-06	PHASE4
NCT03477422	COMPLETED	Urinary Tract Infection Complicated; Acute Pyelonephritis	Venus Remedies Limited	2014-01-11	PHASE3
NCT02784704	COMPLETED	Complicated Intra-abdominal Infections; Complicated Appendicitis	Tetraphase Pharmaceuticals, Inc	2016-10-13	PHASE3
NCT02972255	COMPLETED	Healthy Volunteers	Hoffmann-La Roche	2016-10-31	PHASE1
NCT01732250	COMPLETED	Gram-Negative Bacterial Infections	Mical Paul	2013-03	PHASE4
NCT02486627	COMPLETED	Complicated Urinary Tract Infection; Acute Pyelonephritis	Achaogen, Inc.	2016-01-11	PHASE3
NCT01970371	COMPLETED	Bloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE; Complicated Urinary Tract Infection (cUTI) Due to CRE; Acute Pyelonephritis (AP) Due to CRE	Achaogen, Inc.	2014-09-16	PHASE3
NCT02732327	TERMINATED	Neoplasms; Febrile Neutropenia	Forest Laboratories	2016-05-17	PHASE2
NCT02166476	COMPLETED	Urinary Tract Infection Complicated; Acute Pyelonephritis	Melinta Therapeutics, Inc.	2014-11-20	PHASE3
NCT01808092	COMPLETED	Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)	Pfizer	2013-04	PHASE3
NCT01292031	COMPLETED	Ventilator-associated Bacterial Pneumonia	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2012-05	PHASE3
NCT01992198	UNKNOWN	Pancreatitis,Acute Necrotizing	Erzhen Chen	2012-07	PHASE4
NCT01944319	COMPLETED	Lower Respiratory Tract Infection	Qingtao Zhou	2013-07	PHASE4
NCT02503761	COMPLETED	Late Onset Neonatal Sepsis	Mansoura University	2013-08	PHASE3
NCT01570192	TERMINATED	Bacterial Pneumonia	University of Florida	2010-09	PHASE2
NCT01726023	COMPLETED	Complicated Intra-abdominal Infection	Pfizer	2013-01	PHASE3
NCT02349841	COMPLETED	Pulmonary Tuberculosis	TASK Applied Science	2014-09	PHASE2
NCT01551394	COMPLETED	Sepsis	PENTA Foundation	2012-09	PHASE3
NCT01554124	COMPLETED	Meningitis	PENTA Foundation	2013-02	PHASE1; PHASE2
NCT02344563	COMPLETED	Healthy	Yung Shin Pharm. Ind. Co., Ltd.	2014-09	PHASE4
NCT01499290	COMPLETED	Complicated Intra-Abdominal Infection	Pfizer	2012-03	PHASE3
NCT01455246	TERMINATED	Cirrhosis; Ascites; Nosocomial Spontaneous Bacterial Peritonitis	University of Padova	2010-10	PHASE2; PHASE3
NCT01429259	COMPLETED	Cystic Fibrosis; Pneumonia; Pseudomonas Aeruginosa Infection	Joseph Kuti	2012-02	PHASE4
NCT01158937	TERMINATED	Cystic Fibrosis Pulmonary Exacerbation	Unity Health Toronto	2010-05
NCT02212392	COMPLETED	Acute Pancreatitis	Benazir Bhutto Hospital, Rawalpindi	2013-01	PHASE1; PHASE2
NCT02213796	COMPLETED	Initial Phase of Severe Sepsis and Septic Shock	Sutep Jaruratanasirikul	2013-01	PHASE4
NCT01445678	COMPLETED	Complicated Intra-abdominal Infection	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2011-12-23	PHASE3
NCT01110382	TERMINATED	Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus	Janssen Research & Development, LLC	2010-12	PHASE3
NCT01297842	UNKNOWN	Drug Safety	Mahidol University	2011-05	PHASE4
NCT01633762	COMPLETED	Diabetes; Obesity; Osteoporosis; Inflammation	University Hospital, Gentofte, Copenhagen	2012-04	EARLY_PHASE1
NCT01381562	TERMINATED	Infections, Intestinal	GlaxoSmithKline	2011-10-03	PHASE2
NCT01147640	COMPLETED	Complicated Intra-abdominal Infection	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2010-06-25	PHASE2
NCT01044719	UNKNOWN	Cystic Fibrosis	Imperial College London	2010-01	PHASE4
NCT00579956	UNKNOWN	Melioidosis	University of Oxford	2007-12
NCT00534287	COMPLETED	Severe Sepsis; Septic Shock	Kompetenznetz Sepsis	2007-10	PHASE3
NCT00891423	COMPLETED	Sepsis	Austin Health	2009-04
NCT02506686	COMPLETED	Central Nervous System Infections	Huashan Hospital	2008-09	PHASE4
NCT00752219	COMPLETED	Complicated Intra-abdominal Infections	Pfizer	2009-03-31	PHASE2
NCT00621192	COMPLETED	Necrotizing Enterocolitis; Intra-abdominal Infection	The Emmes Company, LLC	2008-06	PHASE1; PHASE2
NCT00771316	TERMINATED	Urinary Tract Infections	Merck Sharp & Dohme LLC	2008-12	PHASE3
NCT00307099	TERMINATED	Bacterial Infection	National Institute of Allergy and Infectious Diseases (NIAID)	2006-10	PHASE3
NCT00318552	COMPLETED	Sepsis	Pfizer	2002-01	PHASE4
NCT00318994	COMPLETED	Pancreatitis	Pfizer	2002-02	PHASE4
NCT02615041	COMPLETED	Ventilator-Associated Pneumonia	Sutep Jaruratanasirikul	2004-01	PHASE4
NCT00061438	COMPLETED	Pancreatitis, Acute Necrotizing	Pfizer	2003-02	PHASE4
NCT00619710	COMPLETED	Skin Infection; Abscess; Cellulitis	Pfizer	2001-02	PHASE3
NCT00153634	COMPLETED	Cystic Fibrosis; Chronic Bronchitis	Seattle Children's Hospital	2004-03
NCT00438269	COMPLETED	Nosocomial Infection; Pneumonia; Systemic Inflammatory Response Syndrome; Critical Illness; Pyrexia	Canadian Critical Care Trials Group	2003-02	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Check the Meropenem product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a carbapenem antibiotic, meropenem covalently binds to bacterial penicillin-binding proteins to inhibit the cross-linking transpeptidation step essential for peptidoglycan cell wall synthesis. This enzymatic inhibition compromises cell wall structural integrity, triggering osmotic lysis and cell death in susceptible pathogens responsible for conditions evaluated in clinical trials such as hospital-acquired bacterial pneumonia, melioidosis, and septic shock.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).